Argenx sets R&D spotlight on autoimmune myositis, shares stay in Nasdaq and EURO STOXX 50 focus
Published on 06/23/2026 at 20:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-23, 20:21.
Argenx SE (NL0010832176) uses an R&D webinar on autoimmune myositis on June 23, 2026 to sharpen its FcRn pipeline profile, while its ADRs trade on Nasdaq under the ticker ARGX and the stock sits in the EURO STOXX 50 index. The company announced the myositis-focused event in an investor communication and a related Form 6-K filed with the U.S. Securities and Exchange Commission.
What the webinar covers
According to a company announcement summarized by StockTitan, Argenx is hosting an online event titled "R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis" today at 2:00 p.m. Eastern Time, featuring management and external autoimmune disease experts.StockTitan overview of the Argenx webinar The live webcast and subsequent replay are accessible via the investors section of the Argenx website.
A Form 6-K filed on June 23, 2026 references a press announcement as Exhibit 99.1, underscoring that the autoimmune myositis webinar is part of Argenx’s regular U.S. disclosure to Nasdaq investors.Form 6-K filing for June 23, 2026 The company positions the session as a dedicated update on how its FcRn-targeting approach can be extended into additional autoimmune indications.
Analysts keep a constructive stance
Wells Fargo recently raised its Argenx price target to 1,291 U.S. dollars from 1,260 dollars and reiterated an Overweight rating on the shares, according to an analyst roundup cited by Intellectia.ai.Intellectia note on analyst updates and webinar Stifel lifted its target to 1,255 dollars from 1,222 dollars and maintained a Buy recommendation, highlighting the autoimmune rheumatic disease opportunity.
MarketBeat quotes a last regular Nasdaq close of 903.75 dollars for the Argenx ADRs on June 22, 2026 at 4:00 p.m. Eastern Time, with after-hours trading around 920 dollars that evening.MarketBeat price and trading data for ARGX The 52-week range for the shares runs roughly between 664 dollars and 919 dollars, according to compiled data from quantitative screens.
All news and analysis on the Argenx shares
Further company reports, analyst comments and price data on Argenx can be found in the dedicated stock overview and in the investor relations section.
The product behind the stock
Argenx’s commercial flagship is efgartigimod, marketed as Vyvgart for generalized myasthenia gravis and other autoimmune indications, built on the company’s FcRn antagonist platform. The drug reduces pathogenic IgG antibodies and is central to the broader FcRn leadership strategy that the autoimmune myositis webinar highlights.
Where the stock trades today
The Argenx ADRs (NL0010832176) last closed on Nasdaq at 903.75 U.S. dollars on 2026-06-22, 16:00 Eastern Time, based on recent trading data.
Key data on the Argenx shares
- Company: argenx SE
- ISIN: NL0010832176
- WKN: A11602
- Ticker: ARGX
- Trading venue: NASDAQ
- Price (as of 2026-06-22, 16:00): 903.75 USD
- Market cap: 54.4 billion USD (as of 2026-06-22)
- Sector / industry: Health Care / Biotechnology
- Index membership: EURO STOXX 50
- Next earnings date: not officially scheduled
Disclaimer: This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. All data are based on publicly available sources believed to be reliable but cannot be guaranteed for completeness or accuracy.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
